289 related articles for article (PubMed ID: 12127376)
21. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
22. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients.
Zhu Q; McMaster J; Mymin D; Dembinski T; Hatch G; Choy PC; Kroeger EA
Mol Cell Biochem; 2000 Apr; 207(1-2):9-17. PubMed ID: 10888221
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
[TBL] [Abstract][Full Text] [Related]
24. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
[TBL] [Abstract][Full Text] [Related]
25. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
26. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
27. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Ushiroyama T; Nosaka S; Ueki M
Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
[TBL] [Abstract][Full Text] [Related]
28. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
30. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Davignon J
Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
[TBL] [Abstract][Full Text] [Related]
31. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
32. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
[TBL] [Abstract][Full Text] [Related]
33. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
[TBL] [Abstract][Full Text] [Related]
34. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
35. Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Yasuda G; Ando D; Hirawa N; Umemura S
Ren Fail; 2010 Jul; 32(6):680-6. PubMed ID: 20540635
[TBL] [Abstract][Full Text] [Related]
36. Effects of atorvastatin on inflammation and oxidative stress.
Sugiyama M; Ohashi M; Takase H; Sato K; Ueda R; Dohi Y
Heart Vessels; 2005 Jul; 20(4):133-6. PubMed ID: 16025360
[TBL] [Abstract][Full Text] [Related]
37. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
38. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Asztalos BF; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2005 May; 95(9):1025-32. PubMed ID: 15842965
[TBL] [Abstract][Full Text] [Related]
39. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity.
Meng X; Qie L; Wang Y; Zhong M; Li L
Clin Invest Med; 2009 Dec; 32(6):E238. PubMed ID: 20003828
[TBL] [Abstract][Full Text] [Related]
40. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
